Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
$69.61M+95.5%$78M+217%$49.57M+339%$18.13M+54.2%$35.61M+112%
$10.39M+25.6%$8.82M+21.5%$8.2M+13.8%$8.22M+15.6%$8.27M+23.1%
-$21.24M-125%-$26.74M-461%$130.32M+10.4%$118.45M-16.5%$83.82M+111%
$30.7M+34.5%$8.18M-37.9%$21.77M+43.7%$12.3M-27.4%$22.83M+115%
-$122.74M-362%-$21.71M-22.0%-$45.45M-183%-$22.46M-8.5%-$26.55M-311%
$134.67M$2.48B+5,260%$218M$0
$79.36M+290%-$59.06M-50.8%-$10.12M+83.5%-$41.69M-18.8%
-$64.79M-524%-$108.53M-117%$74.53M+86.0%$154.74M+439%$15.28M+866%
-$51.94M-185%-$34.92M-507%$108.54M+5.5%$106.15M-15.0%$60.99M+110%

FAQ

How much cash does Amneal Pharmaceuticals, Inc. generate?
Amneal Pharmaceuticals, Inc. (AMRX) generated $200.8M in operating cash flow over the trailing twelve months.
What is Amneal Pharmaceuticals, Inc.'s free cash flow?
After $72.9M of capital expenditures, Amneal Pharmaceuticals, Inc.'s free cash flow was $127.8M over the trailing twelve months, down 54.8% year over year.
Where does Amneal Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.